65,437 trials
Triple Negative Breast Cancer · Stage IV Breast Cancer · HER2 Negative
Primary: Progression Free Survival (PFS) — 4.1; 2.2 months
Elevated Intraocular Pressure (IOP)
Primary: Mean Percent Intraocular Pressure (IOP) Change — -14.6 mean % Intraocular Pressure (IOP) change
Metastatic Urothelial Cancer
Primary: Objective Response Rate (ORR) as Per Response Evaluation Criteria in Solid Tumors V1.1 (RECIST V1.1) — 37.5 percentage of participants
Presbyopia
Primary: Least Squares Mean Binocular High Contrast/High Illumination Visual Acuity at Distance With Study Lenses — -0.10; -0.09 logMAR
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma · Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
Primary: Objective Response Rate (ORR) — 25 percentage of participants
Agitation in Patients With Dementia of the Alzheimer's Type · Alzheimer Disease · Agitation,Psychomotor
Primary: Change in CMAI Total Score — -15.4; -10.0; -11.5 score on a scale — p=0.010
SARS-CoV2 Infection
Primary: Patient Willingness to Participate in the Study — 30 percentage
Iron Deficiency Anemia · Heavy Menstrual Bleeding · Abnormal Uterine Bleeding
Primary: Percentage of Eligible Patients Enrolled. — 13 Participants
Cognitive Dysfunction · Memory Impairment
Primary: Hopkins Verbal Learning Test-Revised (HVLT-R) - Total — 24.4; 24.5; 26.0; 26.5 score on a scale of 0-36 — p=0.32
COVID-19 · COVID-19 Immunisation
Primary: Number of Participants With Any Medically-attended Adverse Events (MAAEs) — 1; 1; 0; 0 Participants
Kidney Transplant · Hepatitis C · HCV
Primary: Proportion of Patients With Undetectable Hepatitis C Virus (HCV) Polymerase Chain Reaction (PCR) at 12 Weeks After Completion of HCV Treatment — 28 Participants
Acute Leukemia · Hematologic and Lymphocytic Disorder · Myelodysplastic Syndrome
Primary: Graft-versus-host Disease Free Relapse Free (GRFS) at 1 Year — 56 percentage of probability
Colo-rectal Cancer
Primary: Number of Incidence of Device and Procedure Related Serious Adverse Events (SAE) — 0 Participants
Advanced Malignant Solid Neoplasm · Refractory Malignant Solid Neoplasm
Primary: Objective Response Rate (ORR) — 27 percentage
HIV Infections
Primary: Percentage of Participants With Plasma Human Immunodeficiency Viruses (HIV)-1 Ribonucleic Acid (RNA) Greater Than or Equal to (>=) 50 Copies Per Milliliter (c/mL) at…